Rice Hall James & Associates’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,603,458
| Closed | -$24.3M | – | 275 |
|
|
2022
Q3 | $24.3M | Sell |
1,603,458
-241,169
| -13% | -$2.8M | 1.41% | 15 |
|
|
2022
Q2 | $13.8M | Buy |
1,844,627
+166,018
| +10% | +$1.17M | 0.67% | 45 |
|
|
2022
Q1 | $15.3M | Buy |
1,678,609
+475,017
| +39% | +$3.66M | 0.61% | 50 |
|
|
2021
Q4 | $8.45M | Sell |
1,203,592
-29,008
| -2% | -$304K | 0.3% | 71 |
|
|
2021
Q3 | $14.1M | Sell |
1,232,600
-8,083
| -0.7% | -$118K | 0.52% | 60 |
|
|
2021
Q2 | $19.9M | Sell |
1,240,683
-157,383
| -11% | -$2.7M | 0.71% | 49 |
|
|
2021
Q1 | $25M | Buy |
1,398,066
+29,058
| +2% | +$502K | 0.81% | 38 |
|
|
2020
Q4 | $18.5M | Sell |
1,369,008
-43,170
| -3% | -$522K | 0.65% | 47 |
|
|
2020
Q3 | $16.6M | Buy |
1,412,178
+155,260
| +12% | +$1.89M | 0.67% | 48 |
|
|
2020
Q2 | $18.6M | Sell |
1,256,918
-29,213
| -2% | -$432K | 0.8% | 40 |
|
|
2020
Q1 | $17.4M | Buy |
1,286,131
+173,404
| +16% | +$3.29M | 0.97% | 30 |
|
|
2019
Q4 | $26.9M | Buy |
1,112,727
+389,102
| +54% | +$8.06M | 0.91% | 30 |
|
|
2019
Q3 | $13.9M | Buy |
723,625
+185,376
| +34% | +$4.25M | 0.5% | 84 |
|
|
2019
Q2 | $15.9M | Buy |
538,249
+4,992
| +0.9% | +$192K | 0.53% | 69 |
|
|
2019
Q1 | $25.3M | Buy |
533,257
+75,752
| +17% | +$3.33M | 0.82% | 36 |
|
|
2018
Q4 | $16.5M | Buy |
457,505
+179,432
| +65% | +$8.42M | 0.6% | 54 |
|
|
2018
Q3 | $17.1M | Sell |
278,073
-6,689
| -2% | -$430K | 0.61% | 62 |
|
|
2018
Q2 | $19.2M | Buy |
284,762
+9,563
| +3% | +$535K | 0.7% | 52 |
|
|
2018
Q1 | $14.9M | Buy |
275,199
+6,038
| +2% | +$338K | 0.58% | 69 |
|
|
2017
Q4 | $16.1M | Buy |
269,161
+33,927
| +14% | +$2.06M | 0.63% | 65 |
|
|
2017
Q3 | $11.4M | Sell |
235,234
-9,561
| -4% | -$522K | 0.51% | 80 |
|
|
2017
Q2 | $12.9M | Buy |
244,795
+46,482
| +23% | +$2.16M | 0.56% | 77 |
|
|
2017
Q1 | $8.99M | Sell |
198,313
-562
| -0.3% | -$25.1K | 0.44% | 87 |
|
|
2016
Q4 | $7.53M | Buy |
198,875
+817
| +0.4% | +$30.9K | 0.38% | 89 |
|
|
2016
Q3 | $7.47M | Buy |
198,058
+39,126
| +25% | +$863K | 0.39% | 87 |
|
|
2016
Q2 | $2.8M | Buy |
158,932
+1,909
| +1% | +$30.9K | 0.16% | 114 |
|
|
2016
Q1 | $1.91M | Buy |
157,023
+2,790
| +2% | +$44.1K | 0.11% | 179 |
|
|
2015
Q4 | $3.76M | Buy |
154,233
+75,857
| +97% | +$1.77M | 0.21% | 103 |
|
|
2015
Q3 | $1.39M | Buy |
+78,376
| New | +$1.42M | 0.09% | 216 |
|
Rice Hall James & Associates's AERI Position: Q4 2022 in Review
Rice Hall James & Associates sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 1,603,458 shares — an estimated $24.3M sold.
Rice Hall James & Associates first reported a position in AERI in Q3 2015 and held it in 29 quarters. The position peaked at $26.9M in Q4 2019. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Rice Hall James & Associates reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Rice Hall James & Associates sold 1,603,458 Aerie Pharmaceuticals shares in Q4 2022, an estimated $24.3M.
- Rice Hall James & Associates first reported a position in Aerie Pharmaceuticals in Q3 2015 and held it in 29 quarters.
- Rice Hall James & Associates's Aerie Pharmaceuticals position peaked at $26.9M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Rice Hall James & Associates's 13F filing for Q4 2022, filed 27 Jan 2023.